TABLE 2.
Drug | Interacting drug(s) that may decrease antifungal concn | Interacting drug(s) that may increase antifungal concn |
---|---|---|
Itraconazole | Antacidsa including aluminum carbonate (basic), aluminum hydroxide, aluminum phosphate, calcium, dihydroxyaluminum aminoacetate, dihydroxyaluminum sodium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate, sodium bicarbonate; antibiotics including isoniazid, rifabutin, rifampin, rifapentine; antiepileptics including carbamazepine, fosphenytoin, phenytoin; antiretrovirals including darunavir, didanosine, efavirenz, etravirine, nevirapine; H2 blockersa including cimetidine, famotidine, nizatidine, ranitidine, roxatidine; barbituates including phenobarbital; protonpump inhibitorsa including esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole | Antibiotics including clarithromycin; antiretrovirals including amprenavir, darunavir, fosamprenavir, lopinavir, ritonavir |
Voriconazole | Antibiotics including rifabutin, rifampin, rifapentine; antiepileptics including carbamazepine, fosphenytoin, phenytoin; antiretrovirals including amprenavir, darunavir, delavirdine, efavirenz, nevirapine, ritonavir, tipranavir; barbituates including alfuzosin, aprobarbital, butabarbital, eterobarb, heptabarbital, hexobarbital, mephobarbital, pentobarbital, phenobarbital, secobarbital | Antiretrovirals including delavirdine, etravirine, fosamprenavir, nelfinavir, nevirapine, saquinavir, tipranavir, efavirenz; oral contraceptives including ethinyl estradiol, norethindrone; proton pump inhibitors including omeprazole |
Posaconazole | Antiepileptics including phenytoin; H2 blockers including cimetidine, famotidine, nizatidine, ranitidine, roxatidine; proton pump inhibitors including esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole; gastric motility agent including metoclopramide | Antiarrhythmics including quinidine; antibiotics including rifabutin; antiepileptics including phenytoin; antimalarials including halofantrine; antipsychotics including pimozide; antiretrovirals including etravirine; antihistamines including astemizole(off market), terfenadine (off market); benzodiazepines including midazolam; calcium channel blockers including amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil; ergot alkaloids including dihydroergotamine, ergoloid mesylates, ergonovine, ergotamine, methylergonovine, methysergide; immunosuppressants including cyclosporine, sirolimus, tacrolimus; serotonic receptor antagonists including cisapride (off market); statins including atorvastatin, lovastatin, simvistatin; vinca alkaloids including vinblastine, vincristine, vincristine liposome, vinorelbine |
Impact the capsule formulation of itraconazole.